Hormonal
Obesity induces a chronic, low-grade inflammatory state termed 'metainflammation' characterized by the accumulation of proinflammatory M1 macrophages in adipose tissue, which directly impairs insulin signaling and contributes to systemic insulin resistance and type 2 diabetes.
Excess body fat, especially visceral fat, triggers an immune response that actively blocks your body's ability to use insulin efficiently. This isn't just 'being heavy'; it's a biological state of chronic low-grade inflammation. Addressing the underlying inflammation through weight management and metabolic health improvements is key to reversing insulin resistance.
The chronic nature of obesity produces a tonic low-grade activation of the innate immune system that affects steady-state measures of metabolic homeostasis over time... direct and paracrine signals from M1 classically activated macrophages can impair insulin signaling and adipogenesis in adipocytes
Why this rating
Based on a comprehensive review of multiple high-impact studies, animal models, and human genetic associations.
Source
Inflammatory links between obesity and metabolic disease
Carey N. Lumeng et al. · Journal of Clinical Investigation · 2011
DOI 10.1172/jci57132
More from this paper
- Activation of Toll-like receptor 4 (TLR4) by saturated free fatty acids is a primary mechanism linking nutrient excess to inflammation and insulin resistance in metabolic tissues.Strong
- Anti-inflammatory therapies targeting specific pathways (e.g., IKKbeta/NF-kB inhibition with salicylate, IL-1 blockade with anakinra) can improve glycemic control and insulin sensitivity in patients with type 2 diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →